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COX = cyclooxygenase; CRH = corticotropin-releasing hormone; FGF = fibroblast growth factor; HEV = high endothelial venules; HGF = hepatocyte
growth factor; ICAM = intercellular adhesion molecule; IL = interleukin; IFN = interferon; MCP-1 = monocyte chemoattractant protein-1; MHC =
major histocompatibility complex; MMP = matrix metalloproteinase; OA = osteoarthritic; RA = rheumatoid arthritis; TIMP = tissue inhibitor of metallo-
proteinase; TNF = tumour necrosis factor; VCAM = vascular cell adhesion molecule; VEGF = vascular endothelial growth factor.
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflam-
matory disease affecting the joints, and is associated with
increased morbidity and mortality [1–3]. The synovium or
synovial membrane, which surrounds the joint cavity,
becomes massively hypertrophied in RA. This tissue, known
as pannus, can become invasive, penetrating and degrading
the cartilage and bone, resulting in joint deformities, in
functional deterioration and in profound disability.
The lining layer, or intima, of the synovium is normally one
to three cells thick and it comprises macrophage-like cells
and fibroblast-like cells [4]. This layer undergoes thickening
and hypertrophy in RA, largely due to the increased
recruitment of monocytes from the blood supply in the
deeper layer, or subintima, of the tissue [5,6]. Other inflam-
matory cells such as T cells (mainly CD45RO) and B
lymphocytes migrate from the blood into the synovium and
can form ectopic lymphoid follicles around blood vessels.
These structures resemble the lymphoid follicles of lymph
nodes. In addition, neutrophils migrate into the synovium
and end up in large numbers in the synovial joint fluid.
The role of endothelial cells in RA
Endothelial cells are active participants in the inflammatory
process. They are involved in diverse activities including
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Abstract
Endothelial cells are active participants in chronic inflammatory diseases. These cells undergo
phenotypic changes that can be characterised as activated, angiogenic, apoptotic and leaky. In the
present review, these phenotypes are described in the context of human rheumatoid arthritis as the
disease example. Endothelial cells become activated in rheumatoid arthritis pathophysiology,
expressing adhesion molecules and presenting chemokines, leading to leukocyte migration from the
blood into the tissue. Endothelial cell permeability increases, leading to oedema formation and swelling
of the joints. These cells proliferate as part of the angiogenic response and there is also a net increase
in the turnover of endothelial cells since the number of apoptotic endothelial cells increases. The
endothelium expresses various cytokines, cytokine receptors and proteases that are involved in
angiogenesis, proliferation and tissue degradation. Associated with these mechanisms is a change in
the spectrum of genes expressed, some of which are relatively endothelial specific and others are
widely expressed by other cells in the synovium. Better knowledge of molecular and functional
changes occurring in endothelial cells during chronic inflammation may lead to the development of
endothelium-targeted therapies for rheumatoid arthritis and other chronic inflammatory diseases.
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the regulation of leukocyte extravasation, angiogenesis,
cytokine production, protease and extracellular matrix
synthesis, vasodilation and blood vessel permeability, and
antigen presentation [7].
In RA, endothelial cells in the synovium are generally held
to play a central role in the pathophysiology. The cells
achieve this in several ways. First, as a component of blood
vessels in the subintima, endothelial cells allow the migration
of leukocytes such as T cells, B cells, monocytes,
neutrophils and dendritic cells into the joint tissues and
fluid. Endothelial cells undergo activation, expressing
adhesion molecules and presenting chemokines, leading
to leukocyte migration from the blood into the tissue.
Second,  the permeability of endothelial cells increases,
leading to plasma extravasation, to oedema formation and
to swelling of the joint [8]. Third, endothelial cells
proliferate as part of the angiogenic process, which allows
a supply of oxygen and nutrients to the growing pannus.
There is also a net increase in the turnover of endothelial
cells since the number of apoptotic endothelial cells
increases as well as the number of proliferative cells [9].
Finally, endothelial cells express various cytokines,
cytokine receptors and proteases that are involved in
angiogenesis, in proliferation and in tissue degradation.
As part of this spectrum of biological activities, synovial
endothelial cells in RA express a variety of phenotypes
that can be characterised as being activated, angiogenic,
apoptotic and leaky. The intent of the present review is to
examine the pattern of human endothelial cell gene
expression associated with these phenotypic alterations
and to examine whether certain genes are selectively
regulated in endothelial cells and not in other cell types.
(See Table 1 for a summary of genes.)
Morphological and ultrastructural activation
Changes to the endothelium are among the first
pathophysiological events that occur in the human RA
synovium, and these changes occur in venules and
capillaries rather than in arterioles [8,10]. During the first
month of synovitis, these changes include hypertrophy
with the cells becoming cuboidal in morphology, the
development of gaps between endothelial cells and the
presence of multiple concentric layers in the basement
membrane. Associated with these changes is the trans-
endothelial migration of numerous mononuclear and poly-
morphonuclear inflammatory cells.
In another study, synovial biopsies from one patient with
monoarthritis who was subsequently found to have RA
showed endothelial cell proliferation with no detectable
inflammatory infiltrate [8,10]. Endothelial cell proliferation
may thus be the initial event in RA. However, another
study suggested that the recruitment of mononuclear cells
from the blood into the perivascular areas and the lining
layer occurs before endothelial morphological alteration
and proliferation [11].
The cuboidal morphology of the endothelial cells of
synovial venules resembles that of high endothelial
venules (HEV), which are the postcapillary venules of
lymphoid tissues specialised in lymphocyte migration [12].
This change presumably represents a response to
cytokines and other factors that occur in the synovial
milieu, and relates to the increased leukocyte trafficking
into the tissue [13]. The postcapillary venules of the
rheumatoid synovium in patients with active, untreated
disease exhibit HEV-like morphology, especially in regions
near lymphocyte aggregates, whereas tissue samples
from patients whose disease has been modified by
treatment exhibit a flatter endothelium [13,14].
In the skin of primates, HEV-like blood vessels are induced
by stimulation with tumour necrosis factor (TNF)-α and
IFN-γ, which also elicit the adhesion and extravasation of
inflammatory cells [15]. Other studies have shown that
HEV are not absolutely necessary for transendothelial
migration of T cells as migration also occurs through flat
endothelium, although the transit time is considerably
longer [16]. The HEV-like morphology may thus be
associated with the increased leukocyte recruitment that
occurs in synovial inflammation, due to the enhanced or
selective presentation of chemokines and adhesion
molecules, whereas the flatter endothelium may be more
associated with basal leukocyte trafficking.
Many of these changes are not specific to RA, since
cuboidal endothelial cells have been demonstrated in a
variety of inflammatory diseases [12]. In addition, multiple
concentric layers in the basement membrane of capillaries
have been observed in muscle capillaries in other
rheumatic diseases such as systemic lupus erythematosis
and systemic sclerosis [17,18], and in nonrheumatic
diseases such as Duchenne muscular dystrophy [19].
Gene expression associated with leukocyte
migration
Adhesion molecules
As part of leukocyte migration occurring at sites of inflam-
mation, circulating leukocytes adhere to the luminal surface
of the endothelium. This interaction, according to the
current  paradigm, involves the sequential engagement of
leukocyte and endothelial adhesion molecules. First, selectins
and their carbohydrate counterligands mediate leukocyte
tethering and rolling. Leukocyte integrins and their ligands
on endothelial cells, including intercellular adhesion mole-
cules (ICAMs), then mediate firm leukocyte adhesion [20].
Endothelial cells have been shown to express a variety of
adhesion molecules in the RA synovium. As a part of
endothelial activation, several of these molecules are62
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Table 1
Genes expressed by, or ona, endothelial cells in the rheumatoid synovium
Gene Distribution patternb References
Adhesion molecules
E-selectin E, RA > C, P [141]
P-selectin E, RA = C, P [27]
Counterligands for L-selectin (MECA-79 epitope) E, P [25]
HECA 452 epitope EO, RA > C, P [142]
ICAM-1 EO, RA > C, P [33,141]
ICAM-2 EO, RA = C, P [28]
VCAM-1 EO, M, P [29,30] 
Fibronectin EO, RA > C, M, P [31,32]
CD31 (PECAM-1) EO, RA = C, P [27]
CD146 E, RA = C, P [34]
Vascular adhesion protein-1 E, P [35]
CD44 EO, P [27]
VLA1–VLA6 integrins (α1–6β1) EO, P [23]
αVβ3 integrin EO, RA > C, P [27,69]
Chemokines
IL-8 (CXCL8) EO, RA > C, M, P [50]
MCP-1 (CCL2) EO, RA > C, M, P [46,50]
SLC (CCL21) EO, M, P [52,57]
ENA-78 (CXCL5) EO, RA > C, P [48]
SDF-1 (CXCL12) EO, M, P [49,58,60]
MIP-1α (CCL3) EO, RA > C, P [47]
ELC (CCL19) EO, P [52]
Chemokine receptors/binding molecules
CXCR3 EO, P [59]
CXCR4 EO, P [58,60]
Duffy antigen E, M, P [56]
Heparan sulphate proteoglycan EO, P [55]
Angiogenesis regulators and their receptors
FGF-1 and FGF-2 EO, M, P [74,75]
Platelet-derived growth factor receptor EO, M, P [77]
Hepatocyte growth factor activator and receptor EO, RA = C, M, P [78]
Vascular endothelial growth factor EO, P [79,80]
Vascular endothelial growth factor receptors (VEGFR1–VEGFR3) E, RA > C, M, P [81,82]
Transforming growth factor beta 1 EO, RA > C, P [83]
Endoglin (transforming growth factor beta receptor) EO, RA = C, P [83]
Angiopoietin-1 EO, RA > C, P [87]
Tie-1 receptor EO, RA > C, P [88,89]
Angiogenin EO, P [75]
Thrombospondin EO, RA = C, P [69,90]
Pleiotrophin EO, P, M [143]
Angiotensin converting enzyme EO, P [91]
Ets 1 transcription factor EO, RA > C, M, P [92]
Axl tyrosine kinase EO, P [93]
Proinflammatory cytokines, other mediators and their receptors
IL-1 EO, P [97]
Type 1 IL-1 receptor EO, P [97]
IL-1 receptor antagonist EO, P [97]
Tumour necrosis factor alpha EO, RA > C, P [100]
Tumour necrosis factor receptors EO, P [99,103]
IL-15 EO, P [110]
IL-17 receptor E, RA > C, P [112]
Substance P receptor E, P [67]
Parathyroid hormone-related protein E, M, P [144]63
induced or upregulated by cytokines such as TNF-α, IL-1
and IFN-γ [21]. There is good evidence for the presence
of selectins and their counterligands that could promote
leukocyte tethering and rolling [13,22]. E-selectin shows
an endothelial-selective distribution in synovia where its
expression is upregulated in RA compared with osteo-
arthritic (OA) tissue [23]. This adhesion molecule is a
marker of endothelial activation in lymphocyte-rich regions
of the RA synovium [24]. In addition, synovial endothelial
cells situated in inflammatory infiltrates stain positively with
the monoclonal antibody MECA-79 [25]. This antibody
recognises sulphated carbohydrate structures on counter-
ligands for L-selectin [26], which are expressed on HEV
from lymphoid and chronically inflamed tissues [12].
P-selectin has been detected on RA endothelial cells
where its distribution is endothelial selective, and there is
no difference in the level of expression between RA and
control samples [27].
ICAM-1 is a ligand for the β2 integrins of leukocytes and is
present on most RA synovial endothelial cells, as well as
on macrophages and fibroblasts [21,23,28]. ICAM-1
expression is upregulated on these cell types in RA
compared with normal synovium. There is also increased
ICAM-1 expression on cuboidal HEV-like endothelia
compared with ‘flat’ endothelia. ICAM-1, like E-selectin, is
hence considered a marker of endothelial activation.
ICAM-2, another β2 integrin ligand, is mainly expressed on
synovial endothelial cells and not by other cell types
[23,28]. However, this adhesion molecule is expressed by
most RA endothelia and normal endothelia, suggesting
that it is not an activation antigen on these cells. ICAM-3
has been detected on cells of myeloid origin in the
synovium, but there is little or no expression of this
molecule on the endothelium [28]. All three ICAMs are
expressed by RA synovial dendritic cells that also harbour
MHC class II antigens.
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Table 1 (continued)
Genes expressed by, or ona, endothelial cells in the rheumatoid synovium
Gene Distribution patternb References
Kinin B2 receptor EO, RA = C, P [116]
Corticotropin-releasing hormone receptor type 1 EO, RA > C, M, P [113]
Urocortin EO, P [114]
Endothelin-1 E, P [145]
Stem cell factor EO, RA = C, P [118]
Somatostatin receptor (sst2a) EO, P [119]
Midkine EO, RA > C, P [117]
Osteoprotegerin EO, P [146]
Proteases
MMP-1 (collagenase) EO, RA > C, M [120]
MMP-3 (stromelysin) EO, M [122]
MMP-9 (gelatinase B) EO, RA > C, P [123]
MMP-13 (collagenase 3) EO, RA > C, P [124]
Membrane type 1 matrix metalloproteinase EO, RA > C, M [125]
Cathepsin B and cathepsin L EO, RA > C, M [120]
Urokinase plasminogen activator receptor EO, RA > C, P [127]
Tissue-type plasminogen activator E, RA = C, P [128]
TIMP-1 and TIMP-2 EO, RA > C, P [130]
Other genes
MHC class II EO, P [147]
c-fos EO, RA > C, P [138]
Ras EO, P [126]
Pentraxin (PTX3) EO, P [139]
Thy-1 glycoprotein E, P [148]
Prostaglandin E EO, RA > C, P [133]
Cyclooxygenase-2 EO, RA > C, P [132]
Phospholipase A2 activating protein EO, P [134]
Inducible nitric oxide synthase EO, RA > C, M, P [136]
Annexin IV and annexin VI EO, P [140]
aIn the case of soluble mediators such as cytokines, the presence of a protein within a cell does not necessarily mean that it is produced there. It
may be produced elsewhere and bound and internalised by the cell of interest. bE, endothelial selective distribution, a potential marker for these
cells; EO, gene expressed by endothelial and other cells in the synovium; RA < C, gene expression lesser in RA synovium than in control synovium;
RA > C, gene expression greater in RA synovium than in control synovium; RA = C, gene expressed equally in RA synovium and control synovium;
P, protein studied; M, mRNA studied.64
Vascular cell adhesion molecule (VCAM)-1 mRNA and
protein is present in the RA endothelium, albeit weakly,
and is mainly expressed in lining cells and macrophages
[29,30]. The CS-1 isoform of fibronectin is expressed on
the luminal surface of the endothelium and by lining layer
cells in RA synovia, with less expression occurring in
control synovia [22,31,32]. Both VCAM-1 and CS-1
fibronectin are ligands for α4 integrins expressed by
lymphocytes and monocytes, and may be functional in
lymphocyte adhesion to synovial endothelial cells [33].
CD31 (PECAM-1) is present on most synovial endothelial
cells, as well as on macrophages and lining cells, and its
expression on endothelia is comparable in RA and normal
synovia [23,27]. CD146 is a cell adhesion molecule that
belongs to the immunoglobulin supergene family and is
potentially involved in leukocyte–endothelial interactions
[34]. CD146 is expressed almost exclusively by the
vascular endothelium in RA synovia and in normal synovia.
The high levels of soluble CD146 found in RA synovial
fluid, particularly in early disease, may reflect increased
endothelial activity and angiogenesis. Vascular adhesion
protein-1 was originally isolated from synovial endothelial
cells, and it localises selectively to endothelial cells and
not to other cell types in human RA synovia [35]. Vascular
adhesion protein-1 expression is increased in joint
inflammation and is a marker of activated endothelium in
the pig and the dog [36]. Other adhesion molecules
expressed by RA synovial endothelial cells include CD44
and cadherins [13,23,27].
The functional importance of adhesion molecules in human
RA has been shown by the administration of antibodies in
vivo. For example, anti-ICAM-1 treatment in RA patients
with active disease causes a reduction in disease activity
[37] and blocks trafficking of T cells [38]. In another study,
anti-TNF treatment with the antibody infliximab decreases
serum E-selectin and ICAM-1 levels, suggesting that this
may reflect diminished activation of endothelial cells in the
synovium, leading to reduced migration of leukocytes into
human RA joints [39]. Furthermore, administration of anti-
E-selectin in animal models of RA results in a marked
decrease of polymorph and monocyte migration into
arthritic rat joints, and results in inhibition of T-cell
recruitment, causing reduced T-cell-mediated inflam-
mation [40]. VCAM-1 blockade also reduces the clinical
severity in collagen-induced arthritis in mice, most
probably by altering B-cell trafficking [41].
Chemokines
Chemokines play several roles at inflammatory sites. They
initiate firm adhesion of leukocytes to the endothelium by
activating integrins on the leukocyte cell surface [42,43].
Chemokines then direct leukocyte migration across the
endothelium and through the extracellular matrix into the
tissue [44].
There have been numerous reports showing the
expression of chemokines in the RA synovium and the joint
fluid [45], and some of these studies have detected the
presence of chemokine proteins in the endothelium. The
chemokines with an endothelial distribution include
ENA-78 (recently designated CXCL5), IL-8 (CXCL8),
SDF-1 (CXCL12), MCP-1 (CCL2), MIP-1 (CCL3), SLC
(CCL21) and ELC (CCL19) [46–52]. These studies
suggest that RA endothelial cells can produce numerous
chemokines. However, this cannot be stated unequivocally
since nearly all the studies excluded mRNA data. It is
therefore not possible to determine whether the
endothelial cells themselves produce the chemokines or
whether they are produced elsewhere in the synovium,
such as by macrophages or fibroblasts, and the
endothelium is binding and internalising these mediators
as part of the mechanisms of chemokine transcytosis and
presentation to blood leukocytes [20,53,54]. In this
respect, chemokine binding sites for IL-8, MCP-1, MIP-1
and RANTES, which may transcytose and present
chemokines, have been shown to be expressed by the
synovial endothelium [55,56].
A few studies, however, have examined mRNA and protein
expression. In the cases of IL-8, MCP-1 and SLC, their
mRNAs and proteins are present in the RA synovial endo-
thelium [50,57] indicating that such cells can both
synthesise and present these chemokines. In contrast, SDF
mRNA occurs in RA synoviocytes and the protein is
present in endothelial cells, where it is presented attached
to heparan sulphate [58]. There may therefore be
selectivity in the types of chemokines produced by synovial
endothelial cells.
Chemokine receptors and other binding molecules are
expressed by the synovial endothelium. CXCR3 is
expressed by endothelial cells and mononuclear cells in
the lymphoid aggregates of RA synovium [59]. CXCR4 is
present in endothelial cells, synoviocytes and inflammatory
infiltrates in RA and OA synovial tissue [58,60]. The Duffy
antigen/receptor for chemokines, a promiscuous chemo-
kine binding protein, is present on RA and control synovial
endothelial cells, where it shows a selective distribution on
venules [56]. In addition, heparan sulphate proteoglycans,
which bind and present a wide range of chemokines and
other cytokines, are expressed by the synovial endothelial
cells of the RA synovium [55].
Several studies have shown the functional importance of
chemokines in animal models and human RA, and some of
these have been on chemokines produced by synovial endo-
thelial cells. For example, administration of an anti-IL-8
antibody in rabbit experimental arthritis almost completely
blocks the infiltration of neutrophils into the joints and
provides protection from tissue damage in the early phase
of inflammation [61]. In addition, treatment with an MCP-1
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antibody in rat collagen-induced arthritis decreases the
number of macrophages recruited to the joints and
therefore reduces ankle swelling [62]. Some of the effects
of infliximab, a blocking antibody to TNF, in human RA are
mediated by chemokines since patients show reduced
synovial expression of IL-8 and MCP-1 and decreased
leukocyte migration into joints [63].
Gene expression associated with angiogenesis
The formation of new blood vessels, termed angiogenesis,
occurs in the rheumatoid synovium. It is generally
accepted that angiogenesis is central to maintaining and
promoting RA [7,64–66]. The increased endothelial
surface area provides the potential for enhanced leukocyte
recruitment. In addition, angiogenesis is required for the
formation and maintenance of the pannus since the
increased volume of this invasive tissue needs a supply of
oxygen and nutrients. It is proposed that angiogenesis
occurs in several stages. First, at the new branch point the
endothelium becomes activated by cytokines, the blood
vessel permeability increases and the basement
membrane is disrupted by the release of proteolytic
enzymes from the endothelium. The endothelial cells then
proliferate and migrate towards a chemotactic stimulus to
form a new tube, and a new basement membrane is
deposited. The increased permeability of the blood
vessels may be mediated by proinflammatory agents, such
as substance P, and results in tissue oedema. In this
context, substance P receptors have been identified on
endothelial cells in the RA synovium [67].
Evidence for endothelial cell proliferation in the RA synovium
is the expression of cell-cycle-associated antigens (PCNA
and Ki67), the αvβ3 integrin, which is associated with
vascular proliferation, and vascular endothelial growth
factor (VEGF) [68,69]. Interestingly there is an increased
turnover of blood vessels in the RA synovium with focal
regions of angiogenesis and vascular regression.
Increased cell death in the endothelium was shown by
elevated labelling of DNA fragments by terminal
uridyldeoxynucleotide nick-end labelling. This occurred in
the same synovial tissue samples where there was a
concurrent increase in the expression of proliferative
markers. These changes are related to the remodelling of
the synovial vasculature, leading to reduced vascular
densities adjacent to the synovial lining region and to
increased vascular densities in the deeper synovium.
It should be mentioned that the vascularity of the RA
synovium is the subject of ongoing discussions. One
study has shown the mean number of vessels per unit
volume of synovium was higher in RA than in control tissue
[70], whereas another reported that the vessel density
was reduced in the RA synovium [71]. These differences
may, in part, be explained by variation in sampling between
these studies [72,73].
Regulators of angiogenesis
Angiogenesis is regulated by the balance of angiogenic
activators and inhibitors, many of which have been found
in the rheumatoid joint. Several of these substances are
thought to act indirectly by upregulating the expression of
more potent and specific stimuli. Several growth factors
that are capable of promoting angiogenesis are mitogens
that act on a broad range of cell types. For example
fibroblast growth factor (FGF)-1 and FGF-2 stimulate
proliferation, migration and differentiation. FGF-2 mRNA
and protein are expressed by RA synovial endothelial cells,
as well as by fibroblasts and lining cells, and there is no
expression detected in normal synovia [74,75]. Platelet-
derived growth factor (PDGF) is present in the RA
synovium and is angiogenic [76]. It is also a potent
mitogen for fibroblasts and is chemotactic for fibroblasts
and smooth muscle cells. PDGF receptor mRNA and
protein have been demonstrated in vascular endothelial
and smooth muscle cells and in some stromal cells in the
RA synovium [77]. The actions of the angiogenic factor
hepatocyte growth factor (HGF) are dependent on its
activation by HGF activator and binding to a specific HGF
receptor. Both the activator and receptor mRNAs and
proteins are expressed by endothelial cells, fibroblasts and
macrophages in RA and OA synovia [78].
VEGF, in contrast, is a relatively endothelial-specific
angiogenic factor. It has dual activities by eliciting endo-
thelial cell division and increasing vascular permeability,
which may increase oedema, and hence joint swelling, in
RA. VEGF levels in the sera and synovial fluids of patients
with RA are markedly higher than in OA patients or
normal patients [66]. In the RA synovium, VEGF mRNA is
expressed by lining cells and VEGF protein is present on
lining cells, on sublining stromal cells and on the
endothelium of small vessels of the pannus and other
locations [79,80]. The mRNAs and proteins for the VEGF
receptors VEGFR-1, VEGFR-2 and VEGFR-3 are
expressed by RA synovial endothelial cells, where they
are more abundant than in controls [81,82]. These
receptors show an endothelial-selective distribution and
localise in the vicinity of VEGF-producing cells.
Interestingly, VEGF production is upregulated by hypoxia,
and the RA joint is more hypoxic than normal. This has
lead to the suggestion that the formation of new blood
vessels in the pannus may be mediated by hypoxia-driven
expression of VEGF [66].
Endoglin is an angiogenesis inducer. This glycoprotein is a
receptor for transforming growth factor beta and also acts
as an adhesion molecule, containing an arginine–glycine–
aspartic acid (RGD) motif. Endoglin is expressed by RA
synovial, OA synovial and normal synovial endothelial cells,
with little difference in the level of expression between the
three groups [83]. The endoglin ligand (transforming growth
factor beta 1), however, is upregulated on RA synovial
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endothelial cells compared with OA and normal endothelial
cells [83].
Some chemokines are angiogenic, such as IL-8, and
others are angiostatic, such as IP-10 and MIG. Activation
of their respective chemokine receptors results in the
stimulation or inhibition of endothelial cell proliferation and
chemotaxis [84]. Chemokines are mainly expressed by
macrophages and fibroblasts in the RA synovium but also
by endothelial cells, as shown for IL-8 [50,51,85]. Little is
known about the expression of chemokine receptors on
RA synovial endothelial cells. Some recent studies,
however, have shown that CXCR3 (the receptor for IP-10
and MIG) is expressed by the RA synovial endothelium,
suggesting that this receptor mediates the angiostatic
response to these chemokines [59]. CXCR4, which
mediates the proangiogenic activity of SDF, is present in
the synovial endothelium [58,60]. The Duffy antigen may
also have an angiogenic function, and this receptor is
expressed by synovial endothelial cells [56,86].
The angiopoietins and their receptors Tie-1 and Tie-2 play
a key role in the development of the vasculature. Angio-
poietin-1 in adults localises to the endothelium, the lining
cells and the macrophages in the RA synovium, where
levels are higher than in OA or normal synovium [87]. The
expression of Tie-1 and Tie-2 has been reported in the RA
synovium, and there is significant upregulation of Tie-1 on
endothelial cells, on lining cells and on macrophages in
RA compared with normal [87–89]. Angiogenin is a 14
kDa plasma protein that has angiogenic effects, stimulating
endothelial cell proliferation. It codistributes with basic
FGF in the rheumatoid joint, localising to lining cells, to
macrophages and to endothelial cells [75].
Thrombospondin is an inhibitor of angiogenesis and
localises primarily to blood vessels, including endothelial
cells, and to macrophages in the RA synovium [69,90]
Another angiogenesis regulator is angiotensin II, and
angiotensin converting enzyme localises to endothelial
cells and to macrophages in RA synovia [91].
The Ets 1 transcription factor has been intimately linked to
the regulation of angiogenesis and it is induced in
endothelial cells by VEGF. There is upregulation of Ets 1
expression in the RA synovium compared with OA
synovium, with Ets 1 mRNA and Ets 1 protein localising to
endothelial cells of newly formed vessels [92]. Many
growth and survival factors use receptors belonging to the
tyrosine kinase family. One of these tyrosine kinases, Axl,
has been detected in RA synovia, localising to the capillary
endothelium, to vascular smooth muscle cells of blood
vessels and to other cells [93].
Cell adhesion molecules play a role in the regulation of
angiogenesis. In addition to mediating leukocyte adhesion
to the endothelium, VCAM and E-selectin potentiate
angiogenesis, with the latter contributing to the morpho-
genesis of the capillary tube [94]. The invasion, migration
and proliferation of endothelial cells during angiogenesis
are also regulated by integrins [7]. These molecules are
expressed at the cell surface of activated endothelial cells
and interact with a large array of extracellular matrix
proteins. Several integrins have been shown to be
expressed by the RA endothelium [13]. These include β1
integrins, such as α4β1 and α5β1 that bind to fibronectin,
and α6β1 that interacts with laminin. In addition, collagen-
binding integrins are expressed by the vascular endothelium,
including α2β1. αV can associate with several β chains
and can have multiple specificities, including interactions
with vitronectin and fibronectin. αVβ3 is expressed by
several cell types including activated leukocytes and
endothelial cells. It is minimally, if at all, expressed on
resting or normal blood vessels but is highly expressed in
RA synovial blood vessels, where it is viewed as a marker
for endothelial activation [27,69].
The relevance of angiogenesis in the pathophysiology in
RA has been shown in animal models. For example, TNP-
470 (a compound that exerts antiangiogenic, as well as
other, effects) was found to suppress established disease
associated with a marked inhibition of pannus formation
and neovascularisation in type II collagen-induced arthritis
in rats [66,95]. In addition, a soluble form of the Flt-1
VEGF receptor significantly reduces disease severity and
joint destruction in murine collagen-induced arthritis [96].
In human RA, the anti-TNF antibody infliximab reduces
synovial vascularity as assessed by immunostaining for
CD31, von Willebrand factor and αVβ3 integrin [66].
Observations suggest that part of the beneficial effects of
anti-TNF treatment in RA may be related to decreased
production of VEGF and reduced angiogenesis.
Proinflammatory cytokines, other mediators
and their receptors
In the RA synovium IL-1α and IL-1β are mainly secreted by
macrophages, but also localise to endothelial cells and
lymphocytes [97–99]. The type 1 IL-1 receptor is
expressed by the endothelium, by the lining cells and by
other sublining cells in the RA synovium and the cartilage–
pannus junction [97]. A similar pattern of IL-1 receptor
antagonist is found, yet there is less expression. In
addition, antigenic TNF-α mainly localises to macrophages
in the RA lining layer and in the sublining, with some
endothelial and lymphocyte staining [76,100–102]. The
TNF receptors p55 and p75 are expressed by endothelial
cells and a variety of other cell types in the lining and
sublining layers [99,103]. IL-1 and TNF stimulate the
production of degradative proteases and cytokines such
as IL-1, IL-6, IL-8 and MCP-1 by joint tissue cells,
contributing to joint destruction. Many of these cytokines
are also involved in angiogenesis. In addition, IL-1 and
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TNF upregulate the expression of ICAM-1, VCAM-1 and
E-selectin on endothelial cells, stimulating leukocyte
migration into the joint [76,104].
There have been numerous functional studies showing
that blockade of cytokines have anti-inflammatory effects
on RA in animal models and humans. Perhaps the most
striking have been studies on TNF [105]. In humans, the
use of an antibody to TNF (infliximab) or to the soluble
TNF receptor (etanercept) has significantly contributed to
therapy in RA. Use of infliximab results in a significant
reduction in pain, stiffness, number of swollen joints,
serum C-reactive protein and Paulus criteria [106,107].
Interestingly, longer trials reveal that the antibody, in
conjunction with methotrexate, reduces radiographic joint
damage in 50% of patients [108].
There is some evidence that anti-inflammatory cytokines,
such as IL-10 and IL-13, may inhibit leukocyte–endothelial
adhesion and endothelial expression of adhesion molecules
[109]. In the presence of activated leukocytes, however, IL-
10 may also enhance adhesion molecule expression. IL-13
may have proangiogenic effects as it stimulates endothelial
chemotaxis, inferring the expression of IL-13 receptors by
these cells [76]. IL-15 protein localises to the endothelium
and other cell types in the RA synovium [110]. This cytokine
stimulates T-cell migration into RA synovia engrafted into
the SCID mouse. IL-17 is produced by the RA synovium,
induces production of metalloproteinases and could
activate the endothelium enhancing leukocyte extravasation
[111]. In this respect, the IL-17 receptor is expressed in RA
synovia, mainly on endothelial cells, where its expression is
higher than in OA synovia [112].
Elevated levels of corticotropin-releasing hormone (CRH)
are produced locally in the inflamed synovium, and a role
for CRH is indicated in the pathogenesis of inflammatory
joint disease [113]. The CRH receptor type 1 mRNA and
protein are abundantly expressed by RA synovial endo-
thelial cells, as well as by mast cells, where this receptor
may be involved in vascular permeability changes and in
angiogenesis. The receptor is not expressed in normal
synovia. In another study, staining for CRH receptor and
the CRH ligand urocortin was demonstrated in RA
endothelial cells and in a variety of other cell types [114].
Kinin levels are raised in RA and have been implicated in
the pathogenesis of RA by causing release of cytokine
and noncytokine mediators such as IL-1, TNF, PAF,
histamine and prostaglandin E2, which contribute to joint
destruction, leukocyte influx, pain, oedema and angio-
genesis [115]. Kinin B2 receptors have been detected on
synovial endothelial cells, on lining cells and on fibroblasts
in RA and in OA samples [116].
Midkine is a retinoic acid-inducible heparin-binding
cytokine that stimulates neutrophil chemotaxis. The protein
is detected on the endothelial cells and synoviocytes in
inflamed synovia, and less in noninflamed tissue [117].
The protein for stem cell factor, but not its receptor (c-kit),
localises to synovial endothelial cells, macrophages and
fibroblasts in RA and OA synovia [118]. In addition, the
somatostatin receptor (sst2a) protein localises to the RA
synovial endothelium and to macrophages [119].
Proteases
Proteases function in the degradation of the basement
membrane and other regions of the extracellular matrix,
playing a role in angiogenesis and enhancing leukocyte
migration into the tissue [120]. Microvascular endothelial
cells are also present in the invasive synovial pannus, such
as at the cartilage–pannus junction [97,99,103,121].
Proteases released by endothelial cells could therefore
contribute to cartilage and bone destruction caused by the
pannus. In this respect, however, it is not known how much
of a contribution endothelial cells make compared with
other cell types such as fibroblasts and macrophages.
Several proteases are produced by the RA synovial
endothelium. In early RA the mRNAs for matrix metallo-
proteinase (MMP)-1 (collagenase) and the cysteine
proteases cathepsin B and cathepsin L are expressed by
synovial endothelial cells, as shown by in situ hybridisation
[120]. There is only scant expression of these enzymes in
normal synovia. MMP-3 (stromelysin) mRNA mainly occurs
in the lining layer in RA synovia but is also expressed by
endothelial cells [122]. The MMP-9 (gelatinase B) and
MMP-13 (collagenase 3) proteins occur in endothelial
cells, fibroblasts and leukocytes within the RA synovium,
where they occur in elevated levels compared with the OA
synovium [123,124]. Membrane type 1-MMP mRNA is
detected in endothelial cells and fibroblasts of RA synovia,
and there is less expression of the protease in control
synovia [125]. Regarding the regulation of MMP gene
expression, the oncogene Ras (which upregulates MMP-1
and cathepsins) has been shown to colocalise with
cathepsin L in the vessels of the RA synovium [126].
Proteolytic joint destruction in RA is believed to be mediated,
at least in part, by the plasminogen activation system. In this
context the urokinase plasminogen activator receptor is
expressed by RA synovial endothelial cells, occurring in
higher levels compared with normal synovial endothelial
cells. The receptor is also expressed by lining cells and
sublining macrophages [127]. Tissue-type plasminogen
activator also localises to the synovial endothelium in RA and
in OA patients but not to other cell types [128].
Other enzymes such as heparanase and plasmin are
produced and secreted from endothelial cells. These
enzymes may play a role in angiogenesis by releasing growth
factors such as FGF, VEGF and HGF that are bound to
heparan sulphate in the extracellular matrix [84,129].
Available online http://arthritis-research.com/content/6/2/6068
Tissue inhibitor of metalloproteinases (TIMPs) antagonise
the effects of destructive MMPs. The expression of TIMP-1
and TIMP-2 has been shown in endothelial cells and lining
cells in RA synovia but not in normal synovia [130]. It has
been reported that the RA synovial endothelium produces
decreased amounts of TIMP [131]. This may in part
contribute to an imbalance between MMPs and TIMPs in
the RA joint, favouring tissue destruction.
Other genes
Prostaglandins are important mediators of acute and
chronic inflammation [132]. Prostaglandin E has been
localised to the synovial endothelium, to lining cells and to
inflammatory cells, where expression is higher in RA than
in OA tissue [133]. The production of these mediators is
catalysed by an enzyme cascade that includes cyclo-
oxygenases (COXs). There are two isoforms of COX
expressed in the synovium. COX-2 localises to endothelial
cells, to mononuclear leukocytes and to fibroblasts, and
COX-2 expression is increased in inflammatory arthritis
compared with in noninflammatory arthritis [132]. COX-1,
in contrast, is constitutively expressed, particularly by
lining cells, and there is no difference in immunostaining
between inflammatory and noninflammatory arthritis.
Another enzyme involved in prostaglandin synthesis is
phospholipase A2. In this context, phospholipase A2
activating protein has been shown to be present in a
variety of cells in the RA synovium, including endothelial
cells, vascular smooth muscle and monocytes/macro-
phages [134].
Nitric oxide is synthesised by the action of a family of nitric
oxide synthases, which are either constitutive or inducible.
The production of nitric oxide plays a role in inflammation
and physiological processes [135]. The expression of
inducible nitric oxide synthase protein and mRNA has
been shown in RA synovia, localising to the endothelium,
to macrophage-like lining cells and, to a lesser extent, to
fibroblasts [136]. There is only minimal labelling of these
cells in normal synovium. Recent data suggest that nitric
oxide production by inducible nitric oxide synthase has
anti-inflammatory effects in experimental arthritis by mediating
a reduction in leukocyte adhesion and infiltration [137].
Enhanced expression of activation markers, such as the
protooncogene c-fos, has been reported in RA synovial
endothelium compared with OA synovial endothelium
[138]. The pentaxin PTX3 has a structure related to C-
reactive protein and may play a role in inflammatory circuits
in RA. PTX3 is expressed by the endothelium and
synoviocytes in RA synovia [139]. Annexins are calcium-
binding proteins with diverse functions including
regulating inflammation and may have an intracellular role
as cytoskeletal elements in exocytosis and cell
differentiation. Endothelial cells in the RA synovium stain
strongly for annexin IV and annexin VI, and weakly for
annexin I and annexin II [140]. Lymphoid cells are also
strongly positive for annexin VI in the RA synovium.
Conclusions
This review has reported 76 genes expressed by or on the
synovial endothelium in the RA synovium (Table 1). Of
these, 13 genes showed a preferential endothelial
distribution and could be considered potential markers of
these cells. In addition, 29 out of the reported 76 genes
showed increased expression in the RA endothelium in
comparison with non-RA control endothelial cells, and
such genes may be implicated in the pathophysiology of
RA. Future studies of these genes and other pathways
specifically induced in RA endothelial cells may lead to the
development of novel endothelium-targeted therapies for
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